Antiphospholipid syndrome treatment market seen reaching $88.91 billion by 2030

The antiphospholipid syndrome treatment market is projected to grow from $52.78 billion in 2025 to $88.91 billion by 2030, according to The Business Research Company. The report points to rising autoimmune disease prevalence, higher healthcare spending and broader use of anticoagulants as key demand drivers.

Why it matters: - Antiphospholipid syndrome treatment is tied to preventing blood clots, pregnancy complications and organ damage in a complex autoimmune disease. - Faster market growth suggests expanding demand for diagnostics, anticoagulants and specialized care as awareness of the condition increases.

What happened: - The Business Research Company released a market outlook on antiphospholipid syndrome treatment on Oct. 30, 2026. - The report estimates the market will rise from $52.78 billion in 2025 to $58.54 billion in 2026. - The report projects the market will reach $88.91 billion by 2030. - The forecast implies a 10.9% CAGR from 2025 to 2026 and 11.0% CAGR from 2026 to 2030. - Download a free sample of the report.

The details: - The report identifies higher clinical awareness of autoimmune disease as a major growth driver. - Broader use of anticoagulants is supporting market expansion. - Wider availability of diagnostic antibody tests is improving detection and treatment pathways. - Hospital-based treatment protocols are adding to market growth. - Increased recognition of pregnancy-related complications is lifting demand for antiphospholipid syndrome care. - The report says future growth will be supported by precision medicine research, new anticoagulant drugs, digital patient-monitoring tools, specialized autoimmune care centers and thrombosis prevention strategies. - Expected market trends include targeted anticoagulant therapies, personalized treatment plans, earlier diagnosis, combination therapies and closer monitoring of long-term thrombotic risk. - View the full market report.

Between the lines: - The market’s growth outlook reflects a wider rise in autoimmune disease burden, not just antiphospholipid syndrome alone. - The report links the market opportunity to stronger healthcare budgets, which can improve access to medications, testing and specialty care. - UK healthcare spending reached about £317 billion in 2024, up 6.5% from the prior year. - Crohn’s and Colitis Canada estimated in June 2023 that more than 322,600 Canadians had inflammatory bowel disease, and projected that number to rise to about 470,000 by 2035. - North America held the largest market share in 2025, supported by strong healthcare infrastructure, high awareness and faster adoption of advanced therapies.

What's next: - The report expects continued market gains through 2030 as precision medicine and targeted anticoagulants expand. - Wider use of digital monitoring and personalized treatment could shape how antiphospholipid syndrome is managed over the next several years. - The analysis also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa, signaling room for regional growth beyond North America.

The bottom line: - Antiphospholipid syndrome treatment is moving from a niche autoimmune category into a faster-growing global market, with prevention-focused care and better diagnostics driving the next phase of expansion.